Louis T.
- Country
- France
- Department
- Blood Disorders
Research Overview
- Efficacy and Safety of Ianalumab Versus Placebo in Warm Autoimmune Hemolytic Anemia Patients Post-Treatment Failure: A Phase 3 Randomized Double-Blind Study
- Efficacy of Nintedanib in Reducing Total Lesion Glycolysis in Adult Unicentric Hyalino-Vascular Castleman's Disease Over 6-Month Treatment Period
- Long-term Safety and Efficacy Evaluation of Danicopan as an Add-on to Complement Component 5 Inhibitors in Paroxysmal Nocturnal Hemoglobinuria Patients
Data & Insights
Has run more than one trial at 60 of 115 partner sites.
Specializations
Hematological Disorders
This investigator specializes in treating various blood disorders, with particular emphasis on Paroxysmal Nocturnal Hemoglobinuria (PNH). Their research extends to evaluating novel therapeutic approaches and complement inhibitor treatments.
- PNH treatment optimization
- Complement inhibitor therapy
- Long-term treatment safety
Autoimmune Conditions
The investigator focuses on treating immune thrombocytopenia (ITP) and warm autoimmune hemolytic anemia (wAIHA), exploring innovative therapeutic combinations and treatment strategies.
- First-line ITP treatments
- Combination therapy approaches
- Novel therapeutic agents
Rare Diseases
Their expertise includes treating rare conditions such as Unicentric Castleman's disease and Hemophagocytic Lymphohistiocytosis (HLH), investigating targeted therapeutic approaches.
- Rare disease management
- Novel treatment evaluation
- Disease-specific responses
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.